-
High Light
1297538-32-9 Pharmaceutical Intermediates
,API Pharmaceutical Intermediates
,C19H19ClN6O2 Pharmaceutical Intermediates
-
Product NameODM-201
-
SynonymsCS-1565;ODM-201(Darolutamide);N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-[(1RS)-1-hydroxyethyl]-1H-pyrazole-3-carboxamide;0DM021;BAY-1841788;ODM-021;0DM021;ODM 021;ODM 021;ODM-021;ODM-201
-
CAS1297538-32-9
-
MFC19H19ClN6O2
-
MW398.85
-
EINECS829-313-8
-
Boiling Point719.5±60.0 °C(Predicted)
-
Density1.41±0.1 G/cm3(Predicted)
-
Purity99%
-
Place of OriginChina
-
Brand NameRUN
-
CertificationIOS9001
-
Model NumberRUN-Z
-
Minimum Order Quantity10g
-
Priceinquiry
-
Packaging Details10g 50g 100g 500g 1kg
-
Delivery Time3-7 days
-
Payment TermsT/T, MoneyGram, BTCcoin
-
Supply Ability1kg --100kg
1297538-32-9 ODM-201 API C19H19ClN6O2 829-313-8
SECTION 1: Basic information
| ODM-201 Basic information |
| Product Name: | ODM-201 |
| Synonyms: | CS-1565;ODM-201(Darolutamide);N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-[(1RS)-1-hydroxyethyl]-1H-pyrazole-3-carboxamide;0DM021;BAY-1841788;ODM-021;0DM021;ODM 021;ODM 021;ODM-021;ODM-201 |
| CAS: | 1297538-32-9 |
| MF: | C19H19ClN6O2 |
| MW: | 398.85 |
| EINECS: | 829-313-8 |
| Product Categories: | API |
| Mol File: | 1297538-32-9.mol |
 |
|
| ODM-201 Chemical Properties |
| Boiling point | 719.5±60.0 °C(Predicted) |
| density | 1.41±0.1 g/cm3(Predicted) |
| pka | 11.10±0.10(Predicted) |
| ODM-201 Usage And Synthesis |
| Description | ODM-201 is a novel androgen receptor (AR) inhibit designed to inhibit the growth of prostate cancer cells through binding to the AR to inhibit the testosterone-induced AR nuclear translocation. It is particularly used in patients with progressive metastatic castration-resistant prostate cancer. It is effective in inhibiting the activity of some mutant ARs emerging during antiandrogen therapies, including the F876L mutation version which is resistant to enzalutamide and ARN-509 (the second-generation antiandrogens).Therefore, it has potential to overcome the resistance issue occurring upon AR-targeted therapies. |
| References | Moilanen, Anu Maarit, et al. "Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies." Sci Rep 5.2(2015):12007. Fizazi, Karim, et al. "ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data." Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of 2013. Fizazi, K, et al. "Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial." Lancet Oncology 5.9(2014):975-85. |
| ODM-201 Preparation Products And Raw materials |
Related Products
Our products are sold all over the world, you can rest assured.